Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
FORMULATION DEVELOPMENT TECHNOLOGY – A Novel Drug Delivery System That Offers Zero-Order/Near Zero-Order Release Profile of Low-Dosage Strength Tablets Containing Highly Soluble Actives October 5, 2015
Thomas B. Gold, PhD, was awarded a US patent; the intellectual property centers on formulation development technology that allows for the steady, continuous release of API over a particular duration of time to mitigate variations or spikes in therapeutic benefit.
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development April 4, 2024
Biora Therapeutics, Inc. recently shared additional positive interim results from the single-ascending dose (SAD) clinical trial of BT-600, which is...FORMULATION FORUM – Nanoparticle Technologies Used in Ocular Drug Delivery February 29, 2024
Shaukat Ali, PhD, and Jim Huang, PhD, describe the basic understanding of eye diseases, challenges in ocular drug delivery, and the future trends in development of innovative drugs.
VACCINE DEVELOPMENT – A Healthier Global Population Through a Universal Influenza & Multi-Virus Vaccine February 28, 2024
Jeff Fischer, MBA, says we need to have an eye toward universal influenza or multi-virus vaccines that have the ability to provide broad coverage as viral strains continue to evolve.
FORMULATION FORUM – Lipid Nanoparticles – Carriers for Nucleic Acids Delivery January 26, 2024
Shaukat Ali, PhD, and Jim Huang, PhD, describe the role of individual components in aggregation, packing, stability, efficacy, and potency of nucleic acids, the understanding of which is important to achieve better designed and smarter formulations, and robust scale up and manufacturing of LNPs.
SPECIAL ROUNDTABLE – Leadership Panel: 4 Trends That Will Have the Most Impact on Drug Development in 2024 January 26, 2024
Contributor Cindy H. Dubin asked some of today’s life science leaders what they expect will have the greatest impact on drug development in 2024 and beyond.
Vivtex & AI Proteins Enter Strategic R&D Collaboration to Develop Novel, Oral Biologic Therapies for Inflammatory Diseases January 18, 2024
Vivtex Corporation and AI Proteins, Inc. recently announced they have entered a strategic R&D collaboration to develop novel, oral biologic therapies...Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine January 10, 2024
Revive Therapeutics Ltd. recently announced it has completed the formulation development work of its next-generation lyophilized formulation of Bucillamine (New...Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide January 8, 2024
Nanoform Finland Plc recently announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the...Revive Therapeutics Collaborates With Attwill Medical Solutions for the Clinical & Commercial Development of a Novel Lyophilized Formulation of Bucillamine December 18, 2023
Revive Therapeutics Ltd. recently announced it has signed a collaboration agreement with Attwill Medical Solutions LP (AMS) for the clinical...Acumen Pharmaceuticals & Halozyme Enter Global Collaboration & License Agreement to Develop Subcutaneous Formulation of ACU193 With ENHANZE Technology November 6, 2023
Acumen Pharmaceuticals, Inc. recently announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics Inc. to provide Acumen access to Halozyme’s ENHANZE drug delivery technology, based on….
Flashpoint Therapeutics Announces $10M Seed Financing to Pioneer Nanotechnology-Enabled Medicines October 26, 2023
Flashpoint Therapeutics recently announced $10M seed financing round led by Beta Lab, a leading deep tech venture capital firm headquartered...GRI Bio Announces Partnership With the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression October 17, 2023
GRI Bio, Inc. recently announced it has entered into a collaboration with the UK consortia, National Institute for Health and...FORMULATION FORUM – CUBOSOMES – The Next Generation of Lipid Nanoparticles for Drug Delivery October 2, 2023
Jim Huang, PhD, and Shaukat Ali, PhD, shed light on the design and formation of cubosomes with special focus on their applications for delivery of hydrophobic and hydrophilic small and large molecules, including oncology drugs and polynucleotides (DNA, mRNA, and siRNA).
PLATFORM TECHNOLOGY – The PTXΔLNP® Platform: On the Promise of Developing New LNPs for Tomorrow’s mRNA Therapies October 2, 2023
Charlotte Dunne, PhD, Katrin Radloff, PhD, and Leonidas Gkionis, PhD, review the PTXΔLNP platform and how it offers a synergistic sister technology to the mRNA platform to obtain potent mRNA-LNPs for therapeutic applications.
SOLUBILIZING & STABILIZING TECHNOLOGY – CAPTISOL® – Part Perseverance & Part Serendipity October 2, 2023
Vince Antle, PhD, James Pipkin, PhD, and Lian Rajewski, PhD, say with decades of experience, proven safety, and recent and forthcoming authorizations in several new routes of delivery, the Captisol Team is looking forward to the next 2 decades and more of new drug products, new applications, and continued improvement in the technology.
EXECUTIVE INTERVIEW – Sever Pharma Solutions: Development & Manufacturing of High Potent Polymer-Based Dosage Forms September 5, 2023
Tony Listro, Vice President of Technology and Site Lead for SPS’s North American site in Putnam, CT, discusses the company’s recent focus areas as well as current plans for expansion.
Silo Pharma Reaches Positive Milestone With Nasal Formulation for Anxiety, PTSD & Stress-Related Disorders August 8, 2023
Silo Pharma, Inc. recently announced it has advanced the formulation development for its therapeutic drug, SPC-15. The liquid nasal formulation will be used in….
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1 July 31, 2023
PharmAla Biotech Holdings Inc. recently announced it has filed a patent on the composition of matter of PharmAla-1. The patent filing...Ascendia Pharmaceuticals Develops Novel Nanoemulsion IV Formulation for Clopidogrel That Received IND Approval June 26, 2023
Ascendia Pharmaceuticals CEO Jim Huang, PhD, recently announced Ascendia’s patented Emulsol® nanotechnology has been used to develop a novel nanoemulsion IV formulation for….
Company Profiles
Lyophilization Technology, Inc.
Lyophilization Technology, Inc. 30 Indian Drive Ivyland, PA 18974-1431 T: (215) 396-8373 F: (215) 396-8375 E: inquiry@lyo-t.com W: www.lyotechnology.com WHO...CycloLab Cyclodextrin Research & Development Ltd.
CycloLab Cyclodextrin Research & Development Ltd. E: commerce@cyclolab.hu W: cyclolab.hu LinkedIn: https://www.linkedin.com/company/10040240 For more than 30 years, Cyclolab Ltd. has been involved in...
